

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

**POLL RESULTS OF THE RESOLUTIONS PROPOSED AT
THE ANNUAL GENERAL MEETING
HELD ON TUESDAY, 19 MAY 2026**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) is pleased to announce the poll results of the annual general meeting (the “**AGM**”) held at Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, the People's Republic of China (“**PRC**”) at 3:00 p.m. on Tuesday, 19 May 2026.

References are made to the notice and the circular (the “**Circular**”) of the Company both dated 24 April 2026 in relation to the AGM. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

AGM

As at the date of the AGM, the total number of the issued shares of the Company (the “**Shares**”) was 543,494,853 Shares, comprising 197,420,456 unlisted Shares and 346,074,397 H Shares, all of which entitled the holders (or authorised representatives) to attend and vote on the resolutions proposed at the AGM (the “**AGM Resolutions**”). Shareholders or authorised representatives holding an aggregate of 260,077,031 Shares with voting rights, representing approximately 47.852713% of the total number of the Shares with voting rights of the Company were present at the AGM. All Directors attended the AGM.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting on the AGM Resolutions under the Listing Rules. There was no Share entitling the holder to attend the AGM and abstain from voting in favour of the AGM Resolutions under Rule 13.40 of the Listing Rules. No Shareholder has stated the intention in the Circular to vote against or to abstain from voting on the AGM Resolutions.

Pursuant to the Listing Rules and the articles of association of the Company (the “**Articles of Association**”), Computershare Hong Kong Investor Services Limited, representatives from the Shareholders and a member of the board of supervisors of the Company acted as the scrutineers for vote-tabulation at the AGM.

The AGM was convened in compliance with the requirements of the Company Law of PRC and the Articles of Association. Mr. Wenjie Zhang, chairman of the Board, acted as the chairman of the AGM.

POLL RESULTS OF THE AGM RESOLUTIONS

The poll results in respect of the AGM Resolutions are as follows:

Ordinary Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the annual report of the Company and its subsidiaries (the “ Group ”) for the year 2025.	260,077,031 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
2.	To consider and approve the work report of the Board of the Company for the year 2025.	260,077,031 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
3.	To consider and approve the work report of the board of Supervisors of the Company for the year 2025.	260,077,031 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
4.	To consider and approve the final accounts report of the Group for the year 2025.	260,077,031 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
5.	To consider and approve the profit distribution proposal of the Company for the year 2025.	260,077,031 (100.000000%)	0 (0.000000%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

Ordinary Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
6.	To consider and approve the re-appointment of Ernst & Young Hua Ming LLP (Special General Partnership) as the domestic auditors for the Company's financial reports for the year 2026, the re-appointment of Ernst & Young as the international auditors for the Company's financial reports for the year 2026 and the passing of remuneration package for the domestic and international auditors for the year of 2025.	259,722,282 (99.863598%)	354,749 (0.136402%)	0 (0.000000%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
7.	To consider and approve the remunerations of the full-time executive director for the year 2025.	260,077,031 (100.000000%)	0 (0.000000%)	0 (0.000000%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
Special Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
8.	To consider and approve to grant the Board an unconditional general mandate to issue, allot and deal with additional shares in the share capital of the Company.	243,772,708 (93.730964%)	16,302,974 (6.268517%)	1,349 (0.000519%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				
9.	To consider and approve to grant the Board a general mandate to repurchase H shares of the Company.	260,075,682 (99.999481%)	0 (0.000000%)	1,349 (0.000519%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 19 May 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.